Your browser doesn't support javascript.
Plasma-induced nanoparticle aggregation for stratifying COVID-19 patients according to disease severity.
Santopolo, Giulia; Clemente, Antonio; González-Freire, Marta; Russell, Steven M; Vaquer, Andreu; Barón, Enrique; Aranda, María; Socias, Antonia; Del Castillo, Alberto; Borges, Marcio; de la Rica, Roberto.
  • Santopolo G; Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.
  • Clemente A; University of the Balearic Islands (UIB), Chemistry Department, 07122 Palma, Spain.
  • González-Freire M; Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.
  • Russell SM; Translational Research In Aging and Longevity (TRIAL) group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.
  • Vaquer A; Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.
  • Barón E; Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.
  • Aranda M; University of the Balearic Islands (UIB), Chemistry Department, 07122 Palma, Spain.
  • Socias A; Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.
  • Del Castillo A; Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.
  • Borges M; Multidisciplinary Sepsis Unit, ICU, Son Llàtzer University Hospital, 07198 Palma, Spain.
  • de la Rica R; Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.
Sens Actuators B Chem ; 373: 132638, 2022 Dec 15.
Article in English | MEDLINE | ID: covidwho-2031689
ABSTRACT
Stratifying patients according to disease severity has been a major hurdle during the COVID-19 pandemic. This usually requires evaluating the levels of several biomarkers, which may be cumbersome when rapid decisions are required. In this manuscript we show that a single nanoparticle aggregation test can be used to distinguish patients that require intensive care from those that have already been discharged from the intensive care unit (ICU). It consists of diluting a platelet-free plasma sample and then adding gold nanoparticles. The nanoparticles aggregate to a larger extent when the samples are obtained from a patient in the ICU. This changes the color of the colloidal suspension, which can be evaluated by measuring the pixel intensity of a photograph. Although the exact factor or combination of factors behind the different aggregation behavior is unknown, control experiments demonstrate that the presence of proteins in the samples is crucial for the test to work. Principal component analysis demonstrates that the test result is highly correlated to biomarkers of prognosis and inflammation that are commonly used to evaluate the severity of COVID-19 patients. The results shown here pave the way to develop nanoparticle aggregation assays that classify COVID-19 patients according to disease severity, which could be useful to de-escalate care safely and make a better use of hospital resources.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Language: English Journal: Sens Actuators B Chem Year: 2022 Document Type: Article Affiliation country: J.snb.2022.132638

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Language: English Journal: Sens Actuators B Chem Year: 2022 Document Type: Article Affiliation country: J.snb.2022.132638